View more in
Cancer

Dr. Short on the Activity of Ponatinib/Blinatumomab in Ph+ ALL

onclive.com
 2021-06-07

Nicholas J. Short, MD, discusses the efficacy of the combination of ponatinib and blinatumomab in Philadelphia chromosome–positive acute lymphoblastic leukemia. Nicholas J. Short, MD, assistant professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the efficacy of the combination of ponatinib (Iclusig) and blinatumomab (Blincyto) in Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia (ALL).

www.onclive.com

Comments / 0

Comments / 0